On Demand Panel: Meeting on the Med, 2022
Panel Discussion: The Next Normal: Predictions for the Future of Advanced Medicines
Precision attended this year’s Meeting on the Med conference from April 20 – 22nd in Barcelona, Spain. On April 20th our team of experts lead meaningful discussions throughout, providing insights into the clinical development, manufacturing, and commercialization of cell and gene therapies. This panel discussion focused on the sector’s continued success and challenges that lie ahead in research and development, manufacturing, regulatory, pricing, and reimbursement. Watch our panel of industry experts discuss the future of advanced medicines with emerging technologies like gene editing, non-viral delivery methods, and allogeneic cell therapies.
Moderated by Anshul Mangal (President of Project Farma / Precision ADVANCE) this discussion will feature insights from Robert Ang (President & CEO Vor Biopharma), Deb Phippard (CSO Precision for Medicine / Precision ADVANCE), Brent Rice (SVP & CCO Autolus Therapeutics) and Johanna Rossell (CCO Enzyvant Therapeutics).
On-Demand: Public Markets’ Impact on Manufacturing Advanced Therapies
Commercial viability for cell and gene therapy requires the right approach to manufacturing. This webinar, sponsored by Project Farma and Precision ADVANCE addressed public market trends and their impact on the decision to manufacture cell and gene therapies internally or with an external supplier such as a CDMO. Our panel of experts discussed their organizations’ pipeline, the advanced therapy investment landscape, and the regulatory, manufacturing, and commercial requirements for successfully bringing an advanced therapy to market.
Publication: Value of a Cure for Sickle Cell Disease in Reducing Economic Disparities
If a genetic therapy was created to cure sickle cell disease, how might this affect the productivity and earnings of an individual with the disease? How might this change also affect wider economic disparities? PRECISIONheor’s Marlon Graf (Senior Research Economist), Rifat Tuly (Research Scientist), and Jeff Sullivan (Senior Director) recently constructed a model to answer these impactful questions.
Click here to learn more about the model and the team’s findings.
White Paper: What’s Next for Advanced Therapies?
The advanced therapies sector is growing exponentially. The Alliance for Regenerative Medicine (ARM) reports that the sector raised $23.1 billion in 2021 – a 16% year-over-year increase. That figure includes $1.9 billion in private financing and $9.8 billion in venture funding.
This white paper is based on a panel discussion sponsored by Precision ADVANCE at the 2021 Meeting on the Mesa conference and features insights from C-suite leaders on the current CGTx investment landscape, technology innovations, talent shortage and the evolution of reimbursement payment models.
- Anshul Mangal: President (Project Farma & Precision ADVANCE)
- R.A. Session II: President, Founder and CEO (Taysha Gene Therapies)
- Palani Palaniappan: EVP and CTO (Aruvant Sciences)
- Derrell Porter: Founder and CEO (Cellevolve Bio)
- Claudia Zylberberg: Founder and Executive Chair (Akron Bio)
- Phil Cyr: SVP (Precision Value & Health)
Conference: ASGCT Annual Meeting, 2022
Precision experts Travis Harrison: VP, Bioassay Solutions (Precision for Medicine), Reed Lyon: Director, Business Development (Precision for Medicine), and Pallavi Chhabra: Director, Business Development (Precision for Medicine) will be exhibiting at ASGCT Annual from May 16-19 in Washington, D.C. Travis Harrison will also be giving a presentation on, “Key Considerations for Design and Implementation of Nab Bioassays in Gene Therapy Development” on May 17 at 1PM EST.